Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 4
Submit an article Journal homepage
451
Views
48
CrossRef citations to date
0
Altmetric
Original Articles: Research

Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways

Edgar Gil Rizzatti Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
,
Helena Mora-Jensen Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
,
Marc Andrée Weniger Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
,
Federica Gibellini Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
,
Elinor Lee Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
,
Masanori Daibata Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi, Japan
,
Raymond Lai Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
&
Adrian Wiestner Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USACorrespondence[email protected]
, MD, PhD show all
Pages 798-808 | Received 19 Sep 2007, Accepted 06 Jan 2008, Published online: 01 Jul 2009

Citations (48)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Richard Arkwright, Tri Minh Pham, Jeffrey A. Zonder & Q. Ping Dou. (2017) The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Drug Discovery 12:2, pages 225-235.
Read now
Srilatha Nalluri, Susan K Peirce, Rachel Tanos, Haneen A Abdella, Dipan Karmali, Michael D Hogarty & Kelly C Goldsmith. (2015) EGFR signaling defines Mcl-1 survival dependency in neuroblastoma. Cancer Biology & Therapy 16:2, pages 276-286.
Read now
Danyu Sun & Mitchell R Smith. (2014) Bortezomib for the treatment of mantle cell lymphoma. Expert Opinion on Orphan Drugs 2:11, pages 1233-1241.
Read now
Prithviraj Bose, Michael S Batalo, Beata Holkova & Steven Grant. (2014) Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 15:16, pages 2443-2459.
Read now

Articles from other publishers (44)

Kamil Kośmider, Katarzyna Karska, Agata Kozakiewicz, Monika Lejman & Joanna Zawitkowska. (2022) Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia—The State-of-the-Art Knowledge and Future Prospects. International Journal of Molecular Sciences 23:7, pages 3795.
Crossref
Lingjuan Huang, Yanmeng Wang, Ju Bai, Yun Yang, Fangxia Wang, Yuandong Feng, Ru Zhang, Fangmei Li, Peihua Zhang, Nan Lv, Lei Lei, Jinsong Hu & Aili He. (2020) Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress and Chaperones 25:2, pages 357-367.
Crossref
Maria Gonzalez-Santamarta, Grégoire Quinet, Diana Reyes-Garau, Brigitte Sola, Gaël Roué & Manuel S. Rodriguez. 2020. Proteostasis and Disease. Proteostasis and Disease 153 174 .
Scott Best, Taylor Hashiguchi, Adam Kittai, Nur Bruss, Cody Paiva, Craig Okada, Tingting Liu, Allison Berger & Alexey V. Danilov. (2019) Targeting ubiquitin-activating enzyme induces ER stress–mediated apoptosis in B-cell lymphoma cells. Blood Advances 3:1, pages 51-62.
Crossref
Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun & Steven Grant. (2018) Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer 18:1.
Crossref
Ruth Kennedy & Ulf Klein. (2018) Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies. Cells 7:11, pages 189.
Crossref
Ruishan Wang, Andrew M. Davidoff & Lawrence M. Pfeffer. (2016) Bortezomib sensitizes human glioblastoma cells to induction of apoptosis by type I interferons through NOXA expression and Mcl-1 cleavage. Biochemical and Biophysical Research Communications 478:1, pages 128-134.
Crossref
Bryan Hambley, Paolo F. Caimi & Basem M. William. (2016) Bortezomib for the treatment of mantle cell lymphoma: an update. Therapeutic Advances in Hematology 7:4, pages 196-208.
Crossref
Hussein Basma, Sandra E. Ghayad, Ghina Rammal, Angelo Mancinelli, Mohammad Harajly, Farah Ghamloush, Loai Dweik, Rabab El-Eit, Hassan Zalzali, Wissam Rabeh, Claudio Pisano, Nadine Darwiche & Raya Saab. (2016) The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma. International Journal of Cancer 138:6, pages 1528-1537.
Crossref
Thibault Dupont, ShaoNing Yang, Jayeshkumar Patel, Katerina Hatzi, Alka Malik, Wayne Tam, Peter Martin, John Leonard, Ari Melnick & Leandro Cerchietti. (2015) Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget 7:3, pages 3520-3532.
Crossref
T Narita, M Ri, A Masaki, F Mori, A Ito, S Kusumoto, T Ishida, H Komatsu & S Iida. (2015) Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. Blood Cancer Journal 5:12, pages e373-e373.
Crossref
Ling‐Ling Zhao, Yuan‐Fang Liu, Li‐Jun Peng, Ai‐Mei Fei, Wen Cui, Sheng‐Chao Miao, Olivier Hermine, Remy Gressin, Saadi Khochbin, Sai‐Juan Chen, Jin Wang & Jian‐Qing Mi. (2015) Arsenic trioxide rewires mantle cell lymphoma response to bortezomib. Cancer Medicine 4:11, pages 1754-1766.
Crossref
Andrew J. Cowan, Shani L. Frayo, Oliver W. Press, Maria C. Palanca-Wessels, John M. Pagel, Damian J. Green & Ajay K. Gopal. (2015) Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Anti-Cancer Drugs 26:9, pages 974-983.
Crossref
Violetta V. Leshchenko, Pei-Yu Kuo, Zewei Jiang, Marc A. Weniger, Jessica Overbey, Kieron Dunleavy, Wyndham H. Wilson, Adrian Wiestner & Samir Parekh. (2015) Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget 6:29, pages 27332-27342.
Crossref
Ronald Koschny, Christina Boehm, Martin R. Sprick, Tobias L. Haas, Heidrun Holland, Li-Xin Xu, Wolfgang Krupp, Wolf C. Mueller, Manfred Bauer, Thomas Koschny, Marius Keller, Peter Sinn, Juergen Meixensberger, Henning Walczak & Tom M. Ganten. (2014) Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. Journal of Neuropathology & Experimental Neurology 73:11, pages 1034-1046.
Crossref
Ping Zhou, Xun Ma, Lakshmanan Iyer, Chakra Chaulagain & Raymond L. Comenzo. (2014) One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood 123:22, pages 3440-3451.
Crossref
Michael Batalo, Prithviraj Bose, Beata Holkova & Steven Grant. 2014. Resistance to Proteasome Inhibitors in Cancer. Resistance to Proteasome Inhibitors in Cancer 149 179 .
Steve A Maxwell & Seyed Mousavi-Fard. (2013) Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine 238:9, pages 971-990.
Crossref
Moshe E. Gatt, Kohichi Takada, Mala Mani, Mikael Lerner, Marjorie Pick, Teru Hideshima, Daniel E. Carrasco, Alexei Protopopov, Elena Ivanova, Olle Sangfelt, Dan Grandér, Bart Barlogie, John D. ShaughnessyJrJr, Kenneth C. Anderson & Daniel R. Carrasco. (2013) TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. British Journal of Haematology 162:2, pages 210-220.
Crossref
Hyun Joo Jung, Zheng Chen & Nami McCarty. (2012) Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. American Journal of Hematology 87:12, pages 1057-1064.
Crossref
Azmi Yerlikaya, Emrah Okur & Engin Ulukaya. (2012) The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumor Biology 33:5, pages 1385-1392.
Crossref
Beata Holkova & Steven Grant. (2012) Proteasome inhibitors in mantle cell lymphoma. Best Practice & Research Clinical Haematology 25:2, pages 133-141.
Crossref
Mikael Lerner, Moritz Haneklaus, Masako Harada & Dan Grandér. (2012) MiR-200c Regulates Noxa Expression and Sensitivity to Proteasomal Inhibitors. PLoS ONE 7:5, pages e36490.
Crossref
Anthony R. Mato, Tatyana Feldman & André Goy. (2012) Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside. The Oncologist 17:5, pages 694-707.
Crossref
Pascal Gelebart, Zoulika Zak, Mona Anand, Andrew Belch & Raymond Lai. (2012) Blockade of Fatty Acid Synthase Triggers Significant Apoptosis in Mantle Cell Lymphoma. PLoS ONE 7:4, pages e33738.
Crossref
Colby M. Chapman, Xiameng Sun, Mark Roschewski, Georg Aue, Mohamed Farooqui, Lawrence Stennett, Federica Gibellini, Diane Arthur, Patricia Pérez-Galán & Adrian Wiestner. (2012) ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress. Clinical Cancer Research 18:7, pages 1979-1991.
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2012) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 82:1, pages 78-101.
Crossref
Sudha MannavaDaZhong ZhuangJayakumar R. Nair, Rajat BansalJoseph A. WawrzyniakShoshanna N. ZuckerEmily E. FinkKalyana C. MoparthyQiang Hu, Song Liu, Lawrence H. Boise, Kelvin P. Lee & Mikhail A. Nikiforov. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119:6, pages 1450-1458.
Crossref
Hyun Joo Jung, Zheng Chen, Luis Fayad, Michael Wang, Jorge Romaguera, Larry W. Kwak & Nami McCarty. (2012) Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Experimental Hematology 40:2, pages 107-118.e2.
Crossref
Bijal Shah, Peter Martin, Jianguo Tao & Eduardo M. Sotomayor. 2012. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics 113 135 .
Samir Parekh, Marc A. Weniger & Adrian Wiestner. (2011) New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology 21:5, pages 335-346.
Crossref
Ana Mozos, Gaël Roué, Armando López-Guillermo, Pedro Jares, Elias Campo, Dolors Colomer & Antonio Martinez. (2011) The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. The American Journal of Pathology 179:5, pages 2601-2610.
Crossref
Marc A. Weniger, Edgar G. Rizzatti, Patricia Pérez-Galán, Delong Liu, Qiuyan Wang, Peter J. Munson, Nalini Raghavachari, Therese White, Megan M. Tweito, Kieron Dunleavy, Yihong Ye, Wyndham H. Wilson & Adrian Wiestner. (2011) Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clinical Cancer Research 17:15, pages 5101-5112.
Crossref
Yanfen Liu & Yihong Ye. (2011) Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy. Cell Research 21:6, pages 867-883.
Crossref
Patricia Pérez-GalánHelena Mora-JensenMarc A. WenigerArthur L. ShafferIIIIII, Edgar G. RizzattiColby M. ChapmanClifton C. MoLawrence S. StennettChristoph RaderPoching LiuNalini RaghavachariMaryalice Stetler-Stevenson, Constance Yuan, Stefania Pittaluga, Irina Maric, Kieron M. Dunleavy, Wyndham H. Wilson, Louis M. Staudt & Adrian Wiestner. (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 117:2, pages 542-552.
Crossref
Patricia Pérez-Galán, Martin Dreyling & Adrian Wiestner. (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117:1, pages 26-38.
Crossref
Linhua Jin, Yoko Tabe, Kensuke Kojima, Yixin Zhou, Stefania Pittaluga, Marina Konopleva, Takashi Miida & Mark Raffeld. (2010) MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Letters 299:2, pages 161-170.
Crossref
Sarah K. Brennan, Brooke Meade, Qiuju Wang, Akil A. Merchant, Jeanne Kowalski & William Matsui. (2010) Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood 116:20, pages 4185-4191.
Crossref
Andre Goy. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies 308 337 .
Qiuyan Wang, Bidhan A. Shinkre, Jin-gu Lee, Marc A. Weniger, Yanfen Liu, Weiping Chen, Adrian Wiestner, William C. Trenkle & Yihong Ye. (2010) The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group. PLoS ONE 5:11, pages e15479.
Crossref
Z Zak, P Gelebart & R Lai. (2010) Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFα/NF-κB signaling axis. Leukemia 24:8, pages 1476-1486.
Crossref
Shruti Desai, Michelle Maurin, Matthew A. Smith, Sophia C.E. Bolick, Sophie Dessureault, Jianguo Tao, Eduardo Sotomayor & Kenneth L. Wright. (2010) PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib. Molecular Cancer Research 8:6, pages 907-918.
Crossref
P Gelebart, Z Zak, M Anand, J Dien-Bard, H M Amin & R Lai. (2009) Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 23:10, pages 1836-1846.
Crossref
Qiuyan WangHelena Mora-JensenMarc A. WenigerPatricia Perez-GalanChris WolfordTsonwin HaiDavid RonWeiping Chen, William Trenkle, Adrian WiestnerYihong Ye. (2009) ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences 106:7, pages 2200-2205.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.